Skip to main content

Table 3 Multivariable analysis of the impact of clozapine on the onset of appendicitis

From: Relationship between clozapine exposure and the onset of appendicitis in schizophrenia patients: a retrospective cohort study

Variables

 

Univariate

  

Multivariable

 

Odds

95% CI

p-value

Odds

95% CI

p-value

Sex (Woman vs. Man)

1.056

0.294–3.794

.933

-

-

-

Presence of a history of clozapine exposure (Yes vs. No)

6.583

1.851–23.419

.004

6.458

1.674–24.915

.007

Age at the start of treatment for schizophrenia (years old)

0.910

0.832–0.993

.034

0.918

0.835–1.010

.078

Length of the disease duration (years)

0.966

0.908–1.029

.285

-

-

-

Coexistence of diabetes mellitus (Yes vs. No)

1.450 × 10–6

0– -

.990

-

-

-

Regular user of anticholinergic drugs (Yes vs. No)

0.682

0.143–3.258

.632

-

-

-

Regular user of benzodiazepines (Yes vs. No)

3.678

0.461–29.320

.219

-

-

-

Regular user of corticosteroids (Yes vs. No)

7.111

0.791–63.967

.080

9.739

0.863–109.853

.066

Regular user of mood stabilizers (Yes vs. No)

0.704

0.088–5.656

.742

-

-

-

Regular user of laxatives (Yes vs. No)

4.101

1.046–16.073

.043

-

-

-

Regular user of NaSSA (Yes vs. No)

5.506

0.629–48.167

.123

-

-

-

Regular user of NSAIDS (Yes vs. No)

2.824

0.579–13.788

.199

4.840

0.866–27.035

.072

Regular user of SSRI/SNRI (Yes vs. No)

1.423 × 10–6

0– -

.989

-

-

-

Regular user of TCA (Yes vs. No)

8.899 × 104

0– -

.990

-

-

-

  1. Statistically significant values (p < .05) are given in bold
  2. CLZ The clozapine exposure group, non-CLZ The clozapine non-exposure group, SNRIs Serotonin norepinephrine reuptake inhibitors, SSRIs Selective serotonin reuptake inhibitors, NaSSA Noradrenergic and specific serotonergic antidepressant, NSAIDs Non-steroidal anti-inflammatory drugs, TCA Tricyclic antidepressants